Episodes
-
242: How blockbusters get made, new vaccines for RSV, and mRNA's Q score
Not summarized yet
-
241: #JPM23 in review, the year ahead, & the merits of Miami
Not summarized yet
-
240: #JPM23, the future of Alzheimer's, & rising Covid variants
Not summarized yet
-
239: 2022 in review, CEO indictments, & the year ahead
Not summarized yet
-
238: Leaky health data, ASH22, & what it takes to get booed by your peers
Not summarized yet
-
237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing
Not summarized yet
-
236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval
Not summarized yet
-
235: LIVE from the STAT Summit
Not summarized yet
-
234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy
Not summarized yet
-
233: How the biotech revolution could come apart at the seams
Not summarized yet
-
232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms
Not summarized yet
-
231: BU's Covid tinkering, FDA on trial, & why it's hard to take drugs off the market
Not summarized yet
-
230: BIO's messy transition, mRNA's future, & Biogen's next CEO
Not summarized yet
-
229: Nobels for science, biotech dealmaking, & a friendly FTC
Not summarized yet
-
228: A surprise success in Alzheimer's and how FDA history seeded modern controversy
Not summarized yet
-
227: Biden's Covid declaration, twilight of the SPAC, & genome editing 2.0
Not summarized yet
-
226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred
Not summarized yet
-
225: Illumina's $8 billion limbo, a new treatment for ALS, & Emirati biotech funding
Not summarized yet
-
224: The anti-aging research boom, the Godfather of biotech, & the future of Biogen
Not summarized yet
-
223: Fauci's non-retirement, grading biotech VCs, & a bellwether IPO
Not summarized yet
Follow this show on AudioBrevity and new episodes get summarized for you. Create a free account